View Older Stories View More Recent Stories

Apr 4, 2022 12:15AM Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
Mar 28, 2022 07:30AM Biogen (BIIB) and Ionis (IONS) Report Topline Phase 1 Study Results of Drug in C9orf72
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 21, 2022 07:05AM Ionis to present at upcoming investor conferences
Mar 16, 2022 07:17PM Ionis Pharmaceuticals (IONS) Reports Publication of Positive Phase 2 Data for donidalorsen
Mar 16, 2022 07:16PM Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Mar 14, 2022 07:35AM Biogen (BIIB) Presents Updates Across SMA Research Program
Mar 14, 2022 07:30AM Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
Mar 7, 2022 07:05AM Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
Mar 1, 2022 07:05AM Ionis to present at the Cowen Annual Health Care Conference
Feb 24, 2022 07:00AM Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
Feb 10, 2022 07:05AM Ionis to hold full year 2021 financial results webcast
Jan 31, 2022 07:07AM Pfizer (PFE), Ionis (IONS) announce discontinuation of vupanorsen clinical development program
Jan 31, 2022 07:05AM Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
Jan 24, 2022 07:05AM Ionis Pharmaceuticals (IONS) announces eplontersen receives orphan drug designation from U.S. FDA
Jan 24, 2022 07:05AM Ionis announces eplontersen receives orphan drug designation from U.S. FDA
Jan 19, 2022 07:06AM Ionis Pharmaceuticals (IONS) Appoints Joseph Baroldi as Chief Business Officer
Jan 19, 2022 07:05AM Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy
Jan 18, 2022 12:05AM Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
Jan 5, 2022 07:05AM Ionis to present at 40th Annual J.P. Morgan Healthcare conference
Jan 4, 2022 07:34AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Jan 4, 2022 07:34AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Jan 4, 2022 07:31AM Biogen (BIIB) Exercises Option with Ionis (IONS) to Develop and Commercialize Investigational ASO for SMA
Jan 4, 2022 07:30AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Dec 29, 2021 02:00AM Ionis and AstraZeneca close deal to develop and commercialize eplontersen
Dec 7, 2021 02:00AM Ionis and AstraZeneca to develop and commercialize eplontersen
Dec 2, 2021 03:03PM Ionis to hold virtual investor day event
Nov 24, 2021 06:31AM Ionis Pharmaceuticals (IONS) Report Positive Topline Results from Pfizer's (PFE) Phase 2b Study of Vupanorsen
Nov 24, 2021 06:30AM Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen
Nov 18, 2021 01:30PM Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
Nov 12, 2021 07:05AM Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
Nov 9, 2021 07:05AM Ionis to present at upcoming virtual investor conferences
Nov 8, 2021 05:36AM Ionis Pharmaceuticals (IONS) to Present Phase 2 Results of donidalorsen
Nov 7, 2021 07:05AM Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
Nov 3, 2021 07:00AM Ionis reports third quarter 2021 financial results and recent business achievements
Nov 2, 2021 07:05AM Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
Oct 20, 2021 07:05AM Ionis to hold third quarter 2021 financial results webcast
Oct 18, 2021 05:27AM Ionis Pharmaceuticals (IONS) and Biogen (BIIB) Report Updates on tofersen Phase 3 VALOR study in SOD1-ALS
Oct 17, 2021 04:20PM Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
Oct 14, 2021 04:06PM Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Oct 14, 2021 04:06PM Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Sep 15, 2021 07:31AM Biogen (BIIB) to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi
Sep 15, 2021 07:30AM Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Sep 15, 2021 07:30AM Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Sep 3, 2021 07:05AM Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
Sep 2, 2021 07:05AM Ionis to present at upcoming virtual investor conferences
Aug 4, 2021 07:00AM Ionis reports second quarter 2021 financial results and recent business achievements
Aug 2, 2021 09:30AM Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
View More Recent Stories View Older Stories